Condition: Hepatocellular Carcinoma · Biliary Tract Cancer · Sponsor: Replimune, Inc.
The purpose of this study is to assess the efficacy and safety of RP2 in combination with atezolizumab plus bevacizumab (Cohorts 1a and 1b) and RP2 monotherapy (Cohort 2) in the as second line treatment in patients with locally advanced unresectable, recurrent, and/or metastatic HCC and in combination with durvalumab as treatment in patients with unresectable locally advanced or metastatic BTC.
This description comes directly from the study's public registry record.
Clinical Trials at Replimune · 1-781-222-9570 · hccstudy@replimune.com
Clinical Trials at Replimune · +44 1235 242 488 · hccstudy@replimune.com
Always discuss trial participation with your own doctor first.
| Beverly Hills Cancer Center | Beverly Hills, California, United States | Recruiting |
| UC San Diego Moores Cancer Center | La Jolla, California, United States | Recruiting |
| Sylvester Comprehensive Cancer Center (University of Miami Hospital and Clinics) | Miami, Florida, United States | Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
| University of Maryland Medical Center | Baltimore, Maryland, United States | Recruiting |
| Roswell Park Comprehensive Cancer Center | Buffalo, New York, United States | Recruiting |
| Montefiore Medical CenterMontefiore Medical Park | The Bronx, New York, United States | Recruiting |
| University of Pennsylvania, Abramson Cancer Center | Philadelphia, Pennsylvania, United States | Recruiting |
| UPMC Hillman Cancer Center | Pittsburgh, Pennsylvania, United States | Recruiting |
| The West Clinic | Germantown, Tennessee, United States | Recruiting |
| University of Tennessee Medical Center | Knoxville, Tennessee, United States | Recruiting |
| Houston Methodist Hospital Cancer Center | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05733598